# Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

> **NCT07734415** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Inmagene LLC** · enrollment: 400 (estimated)

## Conditions studied

- Atopic Dermatitis
- Atopic Dermatitis Eczema
- Eczema

## Interventions

- **DRUG:** IMG-007

## Key facts

- **NCT ID:** NCT07734415
- **Lead sponsor:** Inmagene LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-06-05
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734415, "Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*